THE 11TH ANNUAL BIOLOGICS MANUFACTURING ASIA 2024
Stelis is proud to sponsor the 11th Annual Biologics Manufacturing Asia 2024 is Asia’s bioprocessing-focused, knowledge-sharing conference that provides regional biopharmaceutical industry stakeholders a carefully tailored networking platform for leveraging opportunities for strategic collaboration, and exposure to the latest manufacturing technologies and know-how.
Exhibit: Meet us at booth # 104
Presentation topic: 5 Elements for Successful Biologics/Biosimilars Development – The CDMO Perspective
Presenter: Prateek Gupta, SVP and Head, Technical Development & MSAT at Stelis Biopharma
Time & Date: Day 2: 21st March 2024, Stream 2, at 9:25 AM.
Abstract:
The biologics CDMO Market size is expected to grow from USD 13.58 billion in 2023 to USD 24.77 billion by 2028, at a CAGR of 12.78%. This growth is primarily driven by significant increase in outsourcing development and manufacturing activities by biotech as well as small and medium-sized pharmaceutical companies, to accelerate their biologic assets (e.g. bispecifics, mAbs and other recombinant proteins) into clinic and avoid the investment risk in capital-intensive manufacturing facilities. To stay competitive, biologics CDMO require not only high technical capability and globally compliant manufacturing facilities, but also unmatched agility and customer advocacy in their DNA to drive desired outcomes for their clients.
This talk will cover the 5 essential and fundamental elements (with examples), that are required for any CDMO to successfully deliver client programs and help them evolve from a mere service provider to a true value partner.